اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها3,020
تعداد مقالات33,758
تعداد مشاهده مقاله45,047,950
تعداد دریافت فایل اصل مقاله49,291,310
Netrebenko, A. S, Gureev, V. V, Pokrovskii, M. V, Gureeva, A. V, Tsuverkalova, Y. M, Rozhkov, I. S. (1400). Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats. سامانه مدیریت نشریات علمی, 76(4), 995-1004. doi: 10.22092/ari.2021.355849.1728
A. S Netrebenko; V. V Gureev; M. V Pokrovskii; A. V Gureeva; Y. M Tsuverkalova; I. S Rozhkov. "Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats". سامانه مدیریت نشریات علمی, 76, 4, 1400, 995-1004. doi: 10.22092/ari.2021.355849.1728
Netrebenko, A. S, Gureev, V. V, Pokrovskii, M. V, Gureeva, A. V, Tsuverkalova, Y. M, Rozhkov, I. S. (1400). 'Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats', سامانه مدیریت نشریات علمی, 76(4), pp. 995-1004. doi: 10.22092/ari.2021.355849.1728
Netrebenko, A. S, Gureev, V. V, Pokrovskii, M. V, Gureeva, A. V, Tsuverkalova, Y. M, Rozhkov, I. S. Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats. سامانه مدیریت نشریات علمی, 1400; 76(4): 995-1004. doi: 10.22092/ari.2021.355849.1728

Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats

Archives of Razi Institute
مقاله 29، دوره 76، شماره 4، آذر و دی 2021، صفحه 995-1004    اصل مقاله (709.96 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.355849.1728
نویسندگان
A. S Netrebenko* ؛ V. V Gureev؛ M. V Pokrovskii؛ A. V Gureeva؛ Y. M Tsuverkalova؛ I. S Rozhkov
Belgorod National Research University, 85 Pobeda St., Belgorod, 308015, Russia
چکیده
Chronic kidney disease (CKD) or acute kidney injury (AKI) causes impaired kidney function, leading to cognitive impairment, neuropathy, and cerebrovascular disease. Due to kidney damage, toxins stay in the blood rather than leaving the body through the urine, and brain function is affected by kidney-brain interaction. The present study aimed to investigate the protective effects of erythropoietin mimetic peptide (pHBSP) and infliximab on ischemic renal reperfusion injury. The experiment was performed on 70 white male Wistar laboratory rats which received recombinant erythropoietin, pHBSP, and infliximab. Under anesthesia, traumatic vascular clamps were applied to the left renal pedicle for 40 min, and nephrectomy was performed on the right. Functional tests and laboratory tests were performed 5 min and 24 h after the reperfusion.  Thereafter, 24 h after the surgery, the plasma creatinine and urea levels in the sham-operated animals were obtained at 45.9±0.8 mmol/L and 6.7±0.2 mmol/L, respectively. Plasma creatinine and urea levels in the control group animals were 102.63±3.6 mmol/L and 21.80±1.29 mmol/L, respectively. The administration of pHBSP and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin. There was a significant decrease in blood levels of creatinine and urea, improvement of microcirculation in the kidney, normalization of glomerular filtration rate, and fractional sodium excretion. The results of the study demonstrated pointed to the prospects of pHBSP and infliximab administration in ischemia-reperfusion kidney injury and justified the feasibility of further research in this field.
کلیدواژه‌ها
Erythropoietin mimetic peptide (pHBSP)؛ Infliximab؛ Ischemia-reperfusion kidney injury؛ Rats؛ Microcirculation
سایر فایل های مرتبط با مقاله
مراجع
  1. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol. 2009;130(1):41-50.
  2. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol. 2011;7(4):189-200.
  3. İhtiyar E, Yaşar NF, Erkasap N, Köken T, Tosun M, Öner S, et al. Effects of doxycycline on renal ischemia reperfusion injury induced by abdominal compartment syndrome. J Surg Res. 2011;167(1):113-20.
  4. Kucuk A, Kabadere S, Tosun M, Koken T, Kinaci M, Isikli B, et al. Protective effects of doxycycline in ischemia/reperfusion injury on kidney. J Physiol Biochem. 2009;65(2):183-91.
  5. Döslüoğlu HH, Aktan AÖ, Yeğen C, Okboy N, Yalçm AS, Yahn R, et al. The cytoprotective effects of verapamil and iloprost (ZK 36374) on ischemia/reperfusion injury of kidneys. Transpl Int. 1993;6(3):138-42.
  6. Erkasap S, Erkasap N, Koken T, Kahraman A, Uzuner K, Yazihan N, et al. Effect of leptin on renal ischemia-reperfusion damage in rats. J Physiol Biochem. 2004;60(2):79-84.
  7. Grossini E, Molinari C, Pollesello P, Bellomo G, Valente G, Mary D, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342(2):376-88.
  8. Batishcheva GA, Zhdanova OA, Nastausheva TL, Chernov YN. Characteristics of adverse side effects of corticosteroid therapy in children with nephrotic syndrome and methods of pharmacological correction. Res Results Pharmacol. 2019;5(1):37-43.
  9. Iu GO. Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity-compound RU-1205. Res Results Pharmacol. 2020;6(3):59-65.
  10. Semeleva EV, Blinova EV, Zaborovsky AV, Gromova IA, Shukurov AS, Blinov DS, et al. Metal-containing taurine compounds protect rat’s brain in reperfusion-induced injury. Res Results Pharmacol. 2020;6(4):43-49.
  11. Voronkov AV, Pozdnyakov DI. Neuroprotective Effect of L-carnitine. Focus on Changing Mitochondrial Function. Res Results Pharmacol. 2020;6(4):29-42.
  12. Palikov VA, Palikova YA, Borozdina NA, Nesmeyanova EN, Rudenko PA, Kazakov VA, et al. A novel view of the problem of Osteoarthritis in experimental rat model. Res Results Pharmacol. 2020;6(2):19-25.
  13. P Basile D, C Yoder M. Renal endothelial dysfunction in acute kidney ischemia reperfusion injury. Cardiovasc Hematol Disord Drug Targets 2014;14(1):3-14.
  14. Elagin VV, Bratchikov OI, Zatolokina MA. Correction of morphofunctional disorders with asialoerythropoietin and selective inhibitor of arginase II KUD975 in cases of ischemic kidney damage in the experiment. Res Results Pharmacol. 2018;4(4): 29-40.
  15. Kostina DA, Pokrovskaya TG, Poltev VY. Renoprotective effect of carbamylated darbepoetin and udenafil in ischemia-reperfusion of rat kidney due to the effect of preconditioning and inhibition of nuclear factor kappa B. Res Results Pharmacol. 2021;7(1):1-19.
  16. Levkova EA, Lugovskoy S, Peresypkina A, Bashuk V. Correction of retinal ischemic injuries by using non-selective imidazoline receptor agonists in the experiment. Res Results Pharmacol. 2019;5(4):7-17.
  17. Skachilova SY, Danilenko L, Kesarev O, Kochkarova I. Pharmacological protection of the ischemic myocardium by derivatives of 3-(2, 2, 2-trimethylhydrazinium) propionate and evaluation of their antioxidant activity. Res Results Pharmacol. 2015;1(1):23-7.
  18. Baker JE. Erythropoietin mimics ischemic preconditioning. Vasc Pharmacol. 2005;42(5-6):233-41.
  19. Belyaeva VS, Stepenko YV, Lyubimov II, Kulikov AL, Tietze AA, Kochkarova IS, et al. Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases. Res Results Pharmacol. 2020;6(3):75-86.
  20. Puchenkova O, Nadezhdin S, Soldatov V, Zhuchenko M, Korshunova D, Kubekina M, et al. Study of antiatherosclerotic and endothelioprotective activity of peptide agonists of EPOR/CD131 heteroreceptor. 2020.
  21. Yu DE. Pharmacological correction of morphofunctional retinal injury using 11-amino acid fragment of darbepoetin in the experiment. Res Results Pharmacol. 2019;5(3):43-55.
  22. Golubev IV, Gureev VV, Korokin MV, Zatolokina MA, Avdeeva EV, Gureeva AV, et al. Preclinical study of innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin. Research Results in Pharmacology. 2020;6(2):85-96.
  23. Carelli S, Marfia G, Di Giulio AM, Ghilardi G, Gorio A. Erythropoietin: recent developments in the treatment of spinal cord injury. Neurol Res Int. 2011;2011.
  24. Pokrovskii M, Yurakova A, Gureev V, Golubev I, Lokteva T, Korokin M, et al. Integrated evaluation of the endothelioprotective activity of an innovative peptide simulating the alpha-helix of b-erythropoethin in L-NAME-induced nitrogen oxide deficiency at the late gestation period. 2019.
  25. Grebien F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, et al. Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. J Am Society Hematol. 2008;111(9):4511-22.
  26. Brines M, Cerami A. Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008;264(5):405-32.
  27. Korokin MV, Soldatov VO, Tietze AA, Golubev IV, Belykh AE, Kubekina MV, et al. 11-amino acid peptide imitating the structure of erythropoietin α-helix b improves endothelial function, but stimulates thrombosis in rats. Pharm Pharmacol. 2019;7(6 (eng)).
  28. Aydin Z, Mallat M, Schaapherder A, van Zonneveld A, van Kooten C, Rabelink T, et al. Randomized trial of short‐course high‐dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant. 2012;12(7):1793-800.
  1. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci. 2008;105(31):10925-30.
  2. Erdogan H, Fadillioglu E, Emre MH. Protection from renal ischemia reperfusion injury by an endothelin-A receptor antagonist BQ-123 in relation to nitric oxide production. Toxicology. 2006;228(2-3):219-28.
  3. Şener G, Şehirli Ö, Velioğlu-Öğünç A, Çetinel Ş, Gedik N, Caner M, et al. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res. 2006;54(1):65-71.
  4. Tasdemir C, Tasdemir S, Vardi N, Ates B, Parlakpinar H, Kati B, et al. Protective effect of infliximab on ischemia/reperfusion-induced damage in rat kidney. Ren Fail. 2012;34(9):1144-9.
33.          Serteser M, Koken T, Kahraman A, Yilmaz K, Akbulut G, Dilek ON. Changes in hepatic TNF-α levels, antioxidant status, and oxidation products after renal ischemia/reperfusion injury in mice. J Surg Res. 2002;107(2):234-40.

آمار
تعداد مشاهده مقاله: 1,516
تعداد دریافت فایل اصل مقاله: 1,457


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب